CRISPR Therapeutics AG
Closed
SectorHealthcare
49.37 -0.72
Overview
Share price change
24h
Min
47.9
Max
50.47
Income | 32M -91M |
|---|---|
Sales | 8.7M 10M |
EPS | -0.94 |
Profit margin | -895.334 |
Employees | 393 |
EBITDA | 7.3M -111M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +42.36% upside |
Next Earnings | 9 Nov 2026 |
|---|
Market Cap | 236M 4.8B |
|---|---|
Previous open | 50.09 |
Previous close | 49.37 |
CRISPR Therapeutics AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CRISPR Therapeutics AG Forecast
Price Target
By TipRanks
42.36% upside
12 Months Forecast
Average 71.167 USD 42.36%
High 110 USD
Low 45 USD
Based on 13 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
